Holen Sie sich die Stockscreener-App
55.96
1.04%
-0.59
Handel nachbörslich:
55.95
-0.010
-0.02%
Schlusskurs vom Vortag:
$56.55
Offen:
$56.925
24-Stunden-Volumen:
2.58M
Relative Volume:
0.96
Marktkapitalisierung:
$9.25B
Einnahmen:
$1.06B
Nettoeinkommen (Verlust:
$-326.58M
KGV:
-26.62
EPS:
-2.1022
Netto-Cashflow:
$-977.73M
1W Leistung:
+5.68%
1M Leistung:
-31.07%
6M Leistung:
-31.87%
1J Leistung:
+32.47%
1-Tages-Spanne:
$55.79
$57.09
1-Wochen-Bereich:
$50.01
$57.48
52-Wochen-Spanne:
$40.03
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
55.96 | 9.35B | 1.06B | -326.58M | -977.73M | -2.1022 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-04-10 | Fortgesetzt | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-10-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Hochstufung | Goldman | Sell → Neutral |
| 2025-09-03 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceutica - The National Law Review
Ionis Pharmaceuticals (IONS) Stock Analysis: Uncovering a Potential 62% Upside in the Biotech Sector - DirectorsTalk Interviews
Ionis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:IONS - TradingView
Ionis Pharmaceuticals, Inc. Revenue Breakdown – DUS:ISI - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Connect - ACCESS Newswire
Ionis Pharmaceuticals Inc (IONS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ionis Pharmaceuticals Inc (IONS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Ionis Pharmaceuticals Inc (IONS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ionis Pharmaceuticals Inc (IONS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ionis Pharmaceuticals Inc (IONS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ionis Pharmaceuticals Inc. (IONS) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
IONS|Ionis Pharmaceuticals Inc|Price:56.550|Chg%:+0.680 - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceuticals, Inc. (IONS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
How Eplontersen’s Phase 3 Setback And Scrutiny At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story - Yahoo Finance
Ionis stock trades steady as genetic medicine pipeline advances and revenue grows - Ad-hoc-news.de
Ionis Pharmaceuticals (IONS) Misses A Key Trial Endpoint, Is The Valuation Now Too Harsh? - Yahoo Finance
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High - Investor's Business Daily
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23%HBSS - Morningstar
Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $110 - Moomoo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc.IONS - PR Newswire
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or uniQure N.V. Stock? - AAII
Canaccord reiterates Ionis stock rating on Tryngolza advantage By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Inc (IONS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Arrowhead rises on phase III hypertriglyceridemia readout - BioWorld News
Plozasiran Phase III Results Expand Cardiometabolic Use - AllSci
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug - BioPharma Dive
Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data - Fierce Pharma
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug - BioSpace
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials (NASDAQ:ARWR) - Seeking Alpha
Earnings Preview: Ionis Pharmaceuticals (IONS) Q2 Earnings Expected to Decline - Yahoo Finance
Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug - Seeking Alpha
Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Ionis Pharmaceuticals, Inc. (IONS) Shows Oversold Potential with Low RSI - GuruFocus
How does Biogen’s novel Alzheimer’s drug compare to approved drugs - MSN
2026-07-21 | Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:IONS | Press Release - Stockhouse
Ionis Pharmaceuticals Stock Slides 39% With A 9-Day Losing Spree - Trefis
Guggenheim cuts Ionis stock price target on Tryngolza sales outlook By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Stock Slides 39% Over 9 Straight Down Days - Trefis
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ionis Pharmaceuticals, Inc. (IONS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmac - The National Law Review
Ionis Pharmaceuticals Stock Slides 37% Over 8 Straight Down Days - Trefis
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: A Biotech Leader with a 70.90% Potential Upside - DirectorsTalk Interviews
Ionis Pharmaceuticals (IONS) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr
2026-07-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ionis Pharmaceuticals, Inc. (IONS) and Encourages Stockholders to Learn More About the Investigation | NDAQ:IONS | Press Release - Stockhouse
(IONS) Risk Channels and Responsive Allocation - Stock Traders Daily
Ionis Pharmaceuticals (IONS) Proxy filing Summary - Quartr
Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceuticals, Inc. (IONS) Investors to Inquire about Securities Investigation - ACCESS Newswire
Cathie Wood Just Bet Big on This Biotech Stock - The Motley Fool
Form 4 Ionis Pharmaceuticals Inc For: 17 July By Investing.com - Investing.com Nigeria
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):